Free Trial
NASDAQ:CCCC

C4 Therapeutics (CCCC) Stock Price, News & Analysis

C4 Therapeutics logo
$1.49 -0.03 (-1.97%)
Closing price 07/3/2025 03:37 PM Eastern
Extended Trading
$1.48 -0.01 (-1.01%)
As of 07/3/2025 04:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About C4 Therapeutics Stock (NASDAQ:CCCC)

Key Stats

Today's Range
$1.44
$1.56
50-Day Range
$1.24
$1.74
52-Week Range
$1.09
$7.66
Volume
728,171 shs
Average Volume
1.32 million shs
Market Capitalization
$105.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.00
Consensus Rating
Moderate Buy

Company Overview

C4 Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
34th Percentile Overall Score

CCCC MarketRank™: 

C4 Therapeutics scored higher than 34% of companies evaluated by MarketBeat, and ranked 730th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    C4 Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    C4 Therapeutics has received no research coverage in the past 90 days.

  • Read more about C4 Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for C4 Therapeutics are expected to decrease in the coming year, from ($1.52) to ($1.70) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of C4 Therapeutics is -1.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of C4 Therapeutics is -1.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    C4 Therapeutics has a P/B Ratio of 0.49. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about C4 Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    9.84% of the float of C4 Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    C4 Therapeutics has a short interest ratio ("days to cover") of 5.8.
  • Change versus previous month

    Short interest in C4 Therapeutics has recently increased by 3.40%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    C4 Therapeutics does not currently pay a dividend.

  • Dividend Growth

    C4 Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.84% of the float of C4 Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    C4 Therapeutics has a short interest ratio ("days to cover") of 5.8.
  • Change versus previous month

    Short interest in C4 Therapeutics has recently increased by 3.40%, indicating that investor sentiment is decreasing.
    • Insider Buying vs. Insider Selling

      In the past three months, C4 Therapeutics insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      Only 8.73% of the stock of C4 Therapeutics is held by insiders.

    • Percentage Held by Institutions

      78.81% of the stock of C4 Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

    • Read more about C4 Therapeutics' insider trading history.
    Receive CCCC Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for C4 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

    CCCC Stock News Headlines

    Cold War Discovery Could Unlock $100 Trillion in Wealth
    Obscure Metal More Valuable than Gold and Bitcoin… COMBINED? This strange "AI Metal" holds the key to the $100 trillion AI boom. Which is why Jeff Brown recently traveled to a location that has one of the highest concentrations of this metal in the world. And you won't believe what he uncovered.
    See More Headlines

    CCCC Stock Analysis - Frequently Asked Questions

    C4 Therapeutics' stock was trading at $3.60 on January 1st, 2025. Since then, CCCC shares have decreased by 58.6% and is now trading at $1.49.

    C4 Therapeutics, Inc. (NASDAQ:CCCC) issued its earnings results on Wednesday, May, 7th. The company reported ($0.37) earnings per share for the quarter, beating analysts' consensus estimates of ($0.48) by $0.11. The firm earned $7.20 million during the quarter, compared to analyst estimates of $3.54 million. C4 Therapeutics had a negative trailing twelve-month return on equity of 45.86% and a negative net margin of 259.60%.

    C4 Therapeutics (CCCC) raised $150 million in an initial public offering on Friday, October 2nd 2020. The company issued 8,800,000 shares at $16.00-$18.00 per share. Jefferies, Evercore ISI, BMO Capital Markets and UBS Investment Bank acted as the underwriters for the IPO.

    Shares of CCCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that C4 Therapeutics investors own include Sangamo Therapeutics (SGMO), Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), Advanced Micro Devices (AMD), NVIDIA (NVDA) and JPMorgan Chase & Co. (JPM).

    Company Calendar

    Last Earnings
    5/07/2025
    Today
    7/06/2025
    Next Earnings (Estimated)
    7/30/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    MED - BIOMED/GENE
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NASDAQ:CCCC
    Fax
    N/A
    Employees
    150
    Year Founded
    N/A

    Price Target and Rating

    Average Stock Price Target
    $12.00
    High Stock Price Target
    $20.00
    Low Stock Price Target
    $4.00
    Potential Upside/Downside
    +705.4%
    Consensus Rating
    Moderate Buy
    Rating Score (0-4)
    2.50
    Research Coverage
    4 Analysts

    Profitability

    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    -$105.32 million
    Net Margins
    -259.60%
    Pretax Margin
    -259.27%

    Debt

    Sales & Book Value

    Annual Sales
    $35.58 million
    Price / Cash Flow
    N/A
    Book Value
    $3.06 per share
    Price / Book
    0.49

    Miscellaneous

    Free Float
    64,808,000
    Market Cap
    $105.80 million
    Optionable
    Optionable
    Beta
    2.94
    Elon Musk's Next Move Cover

    Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

    Get This Free Report

    This page (NASDAQ:CCCC) was last updated on 7/6/2025 by MarketBeat.com Staff
    From Our Partners